---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-043249"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2024-11-01T23:59:59+00:00"
generated_at: "2026-05-30T07:00:19.812108+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma closes $4.5M public offering of stock and warrants for clinical trials

## Summary
- Gross proceeds of ~$4.5M from 395,574 shares, 2.55M pre-funded warrants, 2.95M common warrants at $1.525/unit.
- Proceeds primarily for IND-enabling and Phase I/II trials, including $2.3M to Theradex for Ropidoxuridine Phase II.
- Common warrants exercisable at $1.40 per share, 5-year term; pre-funded warrants at $0.001 per share.
- Placement agents A.G.P./Alliance Global Partners and Boustead Securities, with 9% aggregate cash fee.
- Post-closing shares outstanding: 3,341,673 (excluding warrants).

## SEC filing metadata
- accession: 0001493152-24-043249
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2024-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315224043249/0001493152-24-043249-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315224043249/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-043249
- JSON: https://secwatch.observer/filing/0001493152-24-043249.json
- Plain text: https://secwatch.observer/filing/0001493152-24-043249.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.